Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9P0G3

UPID:
KLK14_HUMAN

ALTERNATIVE NAMES:
Kallikrein-like protein 6

ALTERNATIVE UPACC:
Q9P0G3; A7UNK5; Q1RMZ2; Q6B089

BACKGROUND:
Kallikrein-14, identified by its alternative name Kallikrein-like protein 6, functions as a serine-type endopeptidase with unique substrate specificity akin to both trypsin and chymotrypsin. It is instrumental in seminal clot liquefaction, epidermal desquamation, and activation of various kallikreins and proteinase-activated receptors. Its role in cleaving semenogelin and desmoglein DSG1 underscores its importance in reproductive physiology and skin health. Additionally, Kallikrein-14's involvement in tumor growth, invasion, and angiogenesis marks it as a critical player in cancer biology.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Kallikrein-14 offers a promising avenue for developing novel therapeutic interventions, especially in cancer treatment and managing disorders related to skin desquamation and reproductive system health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.